Natural history of multiple system atrophy in the USA: A prospective cohort study

The Lancet Neurology

Volumn 14, Issue 7, 2015, Pages 710-719

  Low, Phillip A ^a   Reich, Stephen G ^b   Jankovic, Joseph ^c   Shults, Clifford W ^d   Stern, Matthew B ^e   Novak, Peter ^f   Tanner, Caroline M ^g   Gilman, Sid ^h   Marshall, Frederick J ⁱ   Wooten, Frederick ^j   Racette, Brad ^k,l   Chelimsky, Thomas ^m   Singer, Wolfgang ^a   Sletten, David M ^a   Sandroni, Paola ^a   Mandrekar, Jay ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^j UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^k WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^m MEDICAL COLLEGE OF WISCONSIN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ADULT; ARTICLE; CEREBELLAR ATAXIA; COHORT ANALYSIS; COMPOSITE AUTONOMIC SYMPTOMS SCALE; CONSTIPATION; DAILY LIFE ACTIVITY; DEPRESSION; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; IMPAIRED BLADDER EMPTYING; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROGENIC BLADDER; NEUROLOGIC DISEASE ASSESSMENT; ONSET AGE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARKINSONISM; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SHY DRAGER SYNDROME; UNIFIED MULTIPLE SYSTEM ATROPHY RATING SCALE; UNITED STATES; URINE INCONTINENCE; AGED; CLINICAL TRIAL; DISEASE COURSE; MULTICENTER STUDY; MULTIPLE SYSTEM ATROPHY; PARKINSONIAN DISORDERS; PSYCHOLOGY; RETROSPECTIVE STUDY; VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; CEREBELLAR ATAXIA; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSONIAN DISORDERS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84930541886     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00058-7     Document Type: Article

References (22)

1. Wenning GK, Colosimo C, Geser F, Poewe W Multiple system atrophy. Lancet Neurol 2004, 3:93-103.
2. Bower JH, Maraganore DM, McDonnell SK, Rocca WA Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997, 49:1284-1288.
3. Ubhi K, Low P, Masliah E Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci 2011, 34:581-590.
4. Kuzdas-Wood D, Stefanova N, Jellinger KA, et al. Towards translational therapies for multiple system atrophy. Prog Neurobiol 2014, 118:19-35.
5. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst 1998, 74:189-192.
6. Gilman S, Wenning GK, Low PA, et al. Second consensus conference on the diagnosis of multiple system atrophy. Neurology 2008, 71:670-676.
7. Iodice V, Lipp A, Ahlskog JE, et al. Autopsy confirmed multiple system atrophy cases: Mayo experience and role of autonomic function tests. J Neurol Neurosurg Psychiatry 2012, 83:453-459.
8. Figueroa JJ, Singer W, Parsaik A, et al. Multiple system atrophy: prognostic indicators of survival. Mov Disord 2014, 29:1151-1157.
9. Sandroni P, Ahlskog JE, Fealey RD, Low PA Autonomic involvement in extrapyramidal and cerebellar disorders. Clin Auton Res 1991, 1:147-155.
10. Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002, 125:1070-1083.
11. Geser F, Wenning GK, Seppi K, et al. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord 2006, 21:179-186.
12. Lipp A, Sandroni P, Ahlskog JE, et al. Prospective differentiation of multiple system atrophy from Parkinson's disease, with and without autonomic failure. Arch Neurol 2009, 66:742-750.
13. Payan CA, Viallet F, Landwehrmeyer BG, et al. Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS-Parkinson Plus Scale. PLoS One 2011, 6:e22293.
14. Bensimon G, Ludolph A, Agid Y, et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2009, 132:156-171.
15. Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013, 12:264-274.
16. May S, Gilman S, Sowell BB, et al. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord 2007, 22:2371-2377.
17. Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 2004, 19:1391-1402.
18. Suarez GA, Opfer-Gehrking TL, Offord KP, Atkinson EJ, O'Brien PC, Low PA The autonomic symptom profile. A new instrument to assess autonomic symptoms. Neurology 1999, 52:523-528.
19. Ware JE, Snow KK, Kosinski M, Gendek B SF-36 Health Survey: Manual and Interpretation Guide 1993, The Health Institute, New England Medical Center, Boston.
20. Geser F, Seppi K, Stampfer-Kountchev M, et al. The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm 2005, 112:1677-1686.
21. Coon EA, Suarez MD, Ahlskog JE, Mandrekar J, Low PA, Singer W Survival in multiple system atrophy - insights from a large retrospective cohort. Ann Neurol 2014, 76:S39.
22. Low PA, Robertson D, Gilman S, et al. Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014, 13:268-275.